| Unsubscribe |
Dear Reader,
Marc Chaikin just issued a shocking new prediction about AI.
And we encourage anyone with money in the markets to pay very close attention.
Why? Chaikin is one of Wall Street's most respected investment minds.
His former clients have included billionaires like Steve Cohen, owner of the New York Mets...
D.E. Shaw, founder of one of the world's leading money-management firms...
And George Soros, founder of the Quantum Fund with Jim Rogers...
He pioneered computerized trading on Wall Street.
His Chaikin Money Flow indicator is built into every Bloomberg trading terminal on Earth.
He used his 20-factor Power Gauge system to predict:
- The Covid Crash of 2020
- The Stealth Bear of 2022
- The "Liberation Day" Plunge of 2025
- And countless other events going back 50-plus years
His system flashed bullish on Micron before it soared 970% in one year...
Celestica before it soared 6,600%...
And Nvidia before it skyrocketed more than 50,000%...
But he's calling his new prediction the biggest and most important of his career.
According to Chaikin, a $248 trillion "White Swan" event is about to disrupt AI.
It involves a radical new breakthrough in AI data centers.
This new technology uses 99% less electricity.
It uses 99% less water.
It uses 99% less space than current data centers.
Yet it's more than 1 trillion times more powerful when it comes to generating major scientific breakthroughs.
"If our research is correct, This will shorten discovery timelines from years to days or even hours," says the veteran analyst.
That means breakthroughs that would take 5 years with current AI tech will come in just 5 days – accelerating timelines by 360-fold.
One former IBM executive calls this new tech: "A scientific instrument for the ages.
And it could secure America's AI dominance over China for generations.
Which is why the White House is spending billions to expedite the launch right now.
Even better?
The company behind this breakthrough recently flashed "bullish" in Chaikin's system.
Now he says it could be the best AI investment for at least the next 5 years.
Chaikin reveals all the details for free here, in his brand-new presentation.
He even reveals the name and ticker of the company behind the coming breakthrough about halfway through the video.
But fair warning: This is very timely information.
Chaikin says he reserves the right to take it offline at any moment.
So don't wait. Click the link above to check it out while you still can.
Sincerely,
Vic Lederman
Publisher, Chaikin Analytics
P.S. We recommend checking out Marc's presentation right now. Drop whatever you're doing. When this company's new AI tech launches, his research shows it'll render all current AI tech virtually obsolete – instantly. How? By accelerating AI breakthrough times 360X. (Breakthroughs that were supposed to come in 5 years could come in 5 days.) The time to invest is now, he says. And he reveals the full story – and stock ticker – here, for free. Don't delay. This launch will happen before the end of this year.
Microsoft's 8% Dividend Hike: Confidence Signal or Distraction From Capex Math?
Written by Chris Markoch. Originally Published: 9/22/2026.
Key Points
- Microsoft raised its quarterly dividend to 98 cents per share, marking 23 consecutive years of increases while it ramps up massive AI-related capital spending.
- Despite heavy capital expenditures pushing free cash flow down about 6.5% in fiscal 2026, Microsoft's dividend costs roughly $29 billion annually, less than half its free cash flow.
- Analysts remain bullish on Microsoft, with a consensus price target near $567 and Cantor Fitzgerald raising its target to $608 while maintaining an Overweight rating.
- Special Report: One Company Spared After Renewable Credits Get Cut.
Microsoft Corp. (NASDAQ: MSFT) has outperformed the S&P 500 and the Nasdaq in 2026. MSFT is up 31% since the end of June as the company begins to convince investors that it is successfully monetizing artificial intelligence.
Recently, the company gave investors yet another reason to own its stock.
The REAL Reason Trump is Invading Iran (Ad)
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.
Click here to find out what it is.Microsoft’s board of directors authorized a dividend increase on Sept. 14. Starting Dec. 10, 2026, the company’s quarterly payout will be 98 cents per share, a 7.69% increase from the previous payout of 91 cents per share.
This marks 23 consecutive years of dividend increases, putting Microsoft just two years away from becoming a Dividend Aristocrat. But behind that steady payout increase lies a question worth asking: Can Microsoft continue rewarding shareholders while pouring record sums into AI infrastructure?
The Dividend Increase Shrugs Off Cash Concerns
Microsoft has delivered average annual dividend growth of more than 10% over the last three years. That means the recent increase is below the increases of the previous two years on a percentage basis.
The raise also comes as investors grow concerned about Microsoft’s capital expenditures (CapEx) as it continues building out data centers and related AI infrastructure. In its fourth-quarter earnings report for fiscal year 2026 (FY2026), the company reported $41 billion in CapEx.
More importantly, Microsoft expects to spend $50 billion on CapEx in the first quarter of FY2027 and approximately $175 billion for the entire fiscal year.
Does CapEx Impact Free Cash Flow?
The concern about all this spending and the dividend is what it means for free cash flow. If Microsoft’s free cash flow falls too much, would the company have to pause its dividend increases or even cut its dividend?
That may sound alarmist, but it is not unrealistic. Free cash flow is operating cash flow minus cash spent on property and equipment. When CapEx balloons, cash generation must grow just as quickly to keep pace. In the fourth quarter, free cash flow fell 23% to $19.6 billion. CapEx of $41 billion was more than double that amount.
That’s the bad news. The good news is that cash flow is still accelerating. Operating cash flow hit $55.4 billion, up 30%, on strong cloud billings and collections. Cash paid for property and equipment was $35.8 billion, leaving $19.6 billion. For all of FY2026, free cash flow was roughly $67 billion, down about 6.5%. That is a dip, not a collapse, for a company growing revenue by approximately 18%.
Accounting adds a wrinkle. Microsoft extended the useful life of its data center buildings from 15 to 25 years. More leases will also be classified as operating rather than finance leases. Those changes reduced the calendar 2026 CapEx figure from about $190 billion to roughly $175 billion.
Management has flexibility. CFO Amy Hood expects free cash flow to remain positive in FY2027, although she gave no dollar figure. About two-thirds of recent CapEx went toward short-lived assets such as CPUs and GPUs, an area where Microsoft can slow spending if demand softens.
So far, that hasn’t been the case. Azure grew 43% last quarter, and commercial backlog reached $678 billion. Still, $50 billion in planned first-quarter CapEx means quarterly free cash flow could remain under pressure.
However, that is not what the company’s dividend suggests. At 98 cents per quarter, the payout costs roughly $29 billion annually. That is less than half of FY2026 free cash flow. Meanwhile, Bank of America expects the eight largest hyperscalers to burn cash in aggregate this year. Microsoft is still generating cash, which makes the dividend increase sound like confidence rather than strain.
Dividends Are a Bonus, Not the Thesis
A dividend isn’t the best reason to own MSFT. The company remains one of the best ways to invest in the buildout of AI today and in the emerging application phase, which should only strengthen in the coming years.
But if you focus on MSFT’s total return, reinvested dividends over the last 10 years have, by conventional estimates, added around 12% to its growth. To be fair, MSFT has delivered more than 750% growth during that time, so investors have done very well even without the dividend. The company has also spent roughly $165 billion on share repurchases over the last 10 years, further adding to shareholder value.
MSFT's Valuation Looks Fair—But Analysts See Room to Run
Since early August, MSFT has been trading within a defined range, with a price around $490 acting as support. One reason for the slowdown may be the stock’s valuation. At approximately 27 times earnings, the stock is now fairly valued based on its history.
Microsoft analyst forecasts on MarketBeat suggest there is further upside. The consensus price target of around $567 represents about 14% upside. However, recent price targets have been significantly higher. Cantor Fitzgerald, for example, maintained its Overweight rating on MSFT and increased its price target to $608 from $522.
Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
Written by Jeffrey Neal Johnson. Originally Published: 9/22/2026.
Key Points
- Oura plans to debut on the Nasdaq under ticker OURA during the week of Sept. 28, offering 50 million shares priced between $40 and $44 for a valuation up to $15.6 billion fully diluted.
- Oura's subscription revenue grew 121% year over year to $240.5 million, helping lift gross margin to 55% and produce $60.8 million in net income for the nine months ended June 30, 2026.
- Eli Lilly indicated interest in buying up to $100 million of shares and partners with Oura on biometric tracking, reflecting growing pharmaceutical demand for the ring's health data platform.
- Special Report: One Company Spared After Renewable Credits Get Cut.
Oura Inc. (NASDAQ: OURA) launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept. 28. By offering 50 million shares priced between $40 and $44 each, Oura is targeting an initial market capitalization of approximately $12.8 billion to $14.1 billion, or approximately $15.6 billion on a fully diluted basis.
Hardware debuts frequently face investor skepticism over cyclical consumer tastes, yet this transaction presents an evolving financial profile. Backed by direct institutional interest from major pharmaceutical and investment firms, Oura is transforming from a personal wellness device into an essential biometric data layer for metabolic healthcare. Understanding how those fundamentals interact helps clarify where value lies as trading begins.
Oura’s IPO Tests a Premium Valuation
The REAL Reason Trump is Invading Iran (Ad)
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.
Click here to find out what it is.Hardware makers often struggle with uneven revenue because sales depend on multiyear upgrade cycles. When a customer buys a physical device only once every three or four years, total customer lifetime value remains limited. Oura addresses this structural hurdle by pairing titanium rings with an ongoing membership model priced at $5.99 per month.
Regulatory filings reveal how rapidly this recurring model is expanding. For the nine months ended June 30, 2026, membership software revenue grew approximately 121% year over year (YOY) to around $240.5 million. Total net revenue advanced approximately 74% YOY to $1.21 billion during the same period, showing that predictable subscription cash flow is compounding at nearly twice the pace of physical ring shipments.
Oura's engagement metrics help explain that operational momentum. Oura supports approximately five million active paid members across 56 geographic markets. These users record a median daily wear time of 23 hours, while the ratio of daily active users to monthly active users is approximately 65%. The platform also maintains an 85% 12-month paid subscriber retention rate.
In fundamental terms, high user engagement paired with durable retention can lower long-term customer acquisition costs. That operating leverage pushed gross margin up to 55% from 51% in the prior-year period. It also propelled Oura into positive operating profitability, producing $60.8 million in net income and approximately $106.7 million in earnings before interest, taxes, depreciation, and amortization (EBITDA).
Big Pharma Is Buying Into the Ring
The defining fundamental catalyst behind recent institutional demand is the intersection of consumer wearables and clinical metabolic therapy. As millions of patients begin glucagon-like peptide-1 (GLP-1) treatments for diabetes and weight management, medical practitioners face a practical hurdle: monitoring continuous physiological responses outside the clinic.
Oura has entered this workflow by introducing software features that track heart rate variability, changes in sleep quality, and lean muscle retention during weight-loss regimens. That clinical functionality attracted pharmaceutical leader Eli Lilly and Company (NYSE: LLY), which indicated interest in buying up to $100 million of common stock in the offering. Eli Lilly already collaborates with Oura to integrate biometric tracking through the LillyDirect digital healthcare channel, offering patients and doctors continuous data on treatment response.
Expanding that health infrastructure, an operational partnership with continuous biosensor pioneer Dexcom Inc. (NASDAQ: DXCM) connects glucose readings from the Stelo sensor directly to Oura's mobile software.
This integration creates a two-way feedback loop, enabling members to see how nutritional spikes affect overnight resting heart rates and daytime recovery scores. By establishing these clinical connections, Oura is transitioning from a consumer fitness gadget into a continuous-monitoring asset.
How Oura Stacks Up Against Wearable Peers
Evaluating Oura requires balancing hardware production realities against high-margin software multiples. At the midpoint price of $42 per share, Oura trades at approximately 9.7 times annualized sales based on its latest nine-month run rate.
Traditional consumer electronics manufacturers like Garmin Ltd. (NYSE: GRMN) trade closer to 7.5 times sales, while diversified technology leaders like Apple Inc. (NASDAQ: AAPL) command roughly 12 times sales.
Institutional backers, including Dragoneer Investment Group, which indicated an order of up to $300 million, appear comfortable paying a growth premium because Oura is generating 74% top-line revenue growth while delivering positive net income. Many initial public offerings in recent years have entered public markets with widening operating deficits.
Proprietary intellectual property also provides a defensive barrier supporting this multiple. Following patent enforcement proceedings before the U.S. International Trade Commission, Oura secured licensing agreements and recurring royalties from competing smart-ring brands. Those legal protections limit low-cost overseas manufacturers' ability to copy its miniaturized sensor package without paying royalties.
Patent Strength Comes With Legal Risk
Investors should weigh these fundamental advantages against distinct operational risks. Ring hardware sales still generate approximately 80% of total revenue. Despite rapid subscription gains, Oura remains exposed to cyclical swings in discretionary consumer spending and component supply-chain disruptions.
Capital allocation details in the registration filing also deserve close attention. Of the 50 million shares offered, existing stockholders are selling 36.5 million, providing venture backers with significant early liquidity. Of the estimated $532.6 million in net primary proceeds raised at the midpoint, approximately $526.4 million is designated to cover tax withholding and remittance obligations tied to restricted stock unit settlements. That allocation leaves limited primary capital to fund external acquisitions or build cash reserves.
Investors should also track an active consumer class-action lawsuit disclosed in the regulatory paperwork. The litigation challenges the scientific precision and advertising claims related to the accuracy of Oura's sleep-tracking technology. While Oura's patent position remains a strength, an unfavorable outcome in the case could create reputational headwinds or require adjustments to product marketing claims.
What to Watch as Oura Begins Trading
Oura's Nasdaq debut introduces a pure-play health-intelligence business that integrates daily consumer habits with pharmaceutical adherence. With retail access available through brokerages like Robinhood Markets Inc. (NASDAQ: HOOD), opening volume could see active retail participation alongside institutional anchors.
Investors reviewing the debut can monitor where final pricing settles within the $40 to $44 range and watch early price stability as underwriting syndicates balance supply. Cautious investors may prefer to wait for post-listing volatility to subside before establishing an equity position. Long-term investors can use upcoming quarterly earnings reports to confirm whether subscription momentum remains above 120% and gross margin stays near 55% as Oura begins life as a public company.
This message is a sponsored email from Chaikin Analytics, a third-party advertiser of MarketBeat. Why was I sent this message?.
This ad is sent on behalf of Chaikin Analytics, 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. If you would like to optout from receiving offers from Chaikin Analytics please click here.
If you need help with your newsletter, feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, S.D. 57103. United States of America..
No comments:
Post a Comment